GLP-1s Are Becoming "Everything" Drugs: The New Indications Beyond Weight Loss

The dominant theme at the big 2026 medical meetings — APhA's annual conference and the ADA Scientific Sessions — wasn't a new GLP-1. It was a reframing of the ones we already have. GLP-1 drugs have stopped being "diabetes drugs" or "weight-loss drugs" and started being treated as multi-organ metabolic drugs. [1]

That framing is partly real and partly hype, and the useful move is sorting which is which. Here's the honest map: what's actually approved, what has strong data behind it, and what has either failed or is still speculative.

Why GLP-1 receptors show up everywhere

The mechanistic reason this is even plausible: GLP-1 and related receptors aren't only in the pancreas. They're expressed in the brain, heart, kidney, blood vessels, and liver. So a drug that activates them produces effects that ripple across multiple organ systems — which is exactly why the indication list keeps expanding. [2]

Column 1 — Actually approved (FDA-stamped)

These aren't promises; they're on the label.

Cardiovascular risk. Semaglutide (Wegovy) is approved to reduce the risk of major cardiovascular events — heart attack, stroke, cardiovascular death — in adults with established heart disease and obesity, on the strength of the SELECT trial. [1]
Obstructive sleep apnea. Tirzepatide (Zepbound) was approved on December 20, 2024 for moderate-to-severe OSA in adults with obesity — the first incretin drug to win a sleep-apnea indication. [1][3]
MASH (liver disease). Semaglutide (Wegovy) received accelerated approval in August 2025 for metabolic dysfunction-associated steatohepatitis (MASH), the serious form of fatty liver disease, and GLP-1s are now positioned as preferred agents for patients with type 2 diabetes and biopsy-proven MASH. [1]

Column 2 — Strong trial data, building toward indications

Kidney disease. In the Phase 3 FLOW trial, semaglutide 1 mg reduced the risk of major kidney events by 24% in patients with type 2 diabetes and chronic kidney disease — a large, hard-outcome result. [1]
Heart failure. GLP-1s have shown symptom and functional improvement in obesity-related heart failure with preserved ejection fraction (HFpEF), an area with few good options.

This is the column where "everything drug" is most justified: real endpoints, real trials, plausibly headed to labels.

Column 3 — Failed, or still hype

This is the column the breathless coverage tends to skip, and it's the most important one for calibration.

Alzheimer's disease — this one failed. The Phase 3 EVOKE and EVOKE+ trials tested oral semaglutide 14 mg in people with early symptomatic Alzheimer's. The result: no statistically significant difference versus placebo on the primary cognitive measure (the Clinical Dementia Rating–Sum of Boxes). [1] The GLP-1-for-the-brain story is genuinely interesting in early science, but the biggest, most rigorous test of it so far came back negative. Anyone selling GLP-1s as an Alzheimer's play is ignoring the EVOKE readout.
Addiction. GLP-1s appear to dampen reward-pathway signaling, and early data in alcohol and nicotine use are intriguing — but the studies are small and early, and this is nowhere near an established use. [2]
PCOS and others. Real off-label interest, limited rigorous trial data so far.

The takeaway

"GLP-1s are everything drugs" is about half true. The approved expansions — cardiovascular, sleep apnea, MASH — are real and important, and the kidney data is strong. But the frontier claims are where it gets oversold: the marquee Alzheimer's trial failed, and the addiction story is still early. The honest summary is that GLP-1s are turning out to be remarkably broad metabolic drugs with clear limits — and the limits get quietly dropped from the hype.

For the compounds driving all this, we keep live price comparisons and research profiles for semaglutide, tirzepatide, and retatrutide — the last of which posted its own multi-organ data (knee OA, sleep apnea) at ADA 2026.

This article summarizes publicly reported clinical-trial data for educational purposes and is not affiliated with Novo Nordisk or Eli Lilly. For research purposes only. Not medical advice. Always consult a licensed physician.

Sources

Drug Topics. "GLP-1s Taking Over Indications Outside of Diabetes and Weight-Loss | APhA 2026." drugtopics.com
Pharmacy Times. "APhA2026: GLP-1 Therapies Are Rewriting the Rules of Metabolic Disease." pharmacytimes.com
Nature Medicine. "The expanding landscape of GLP-1 medicines." nature.com